Stevanato Group Posts 7% FY25 Revenue Growth, Expanded Margins; Issues Upbeat FY26 Guidance
summarizeSummary
Stevanato Group announced strong fiscal year 2025 results, with revenue increasing 7% (9% constant currency) to EUR1.186 billion, driven by record high-value solutions revenue and expanded gross and adjusted EBITDA margins. Diluted EPS grew 19% to EUR0.51. The company also provided positive fiscal year 2026 guidance, projecting revenue between EUR1.26 billion and EUR1.29 billion and adjusted diluted EPS of EUR0.59 to EUR0.63. The robust performance, particularly in high-value solutions (46% of total revenue) and the Biopharmaceutical and Diagnostic Solutions segment, indicates strong demand and effective strategy execution. The significant contribution from GLP1s (19-20% of revenue) highlights a key growth driver. The positive 2026 outlook provides investors with confidence in continued growth and profitability. Investors will monitor the company's ability to meet its 2026 guidance, sustain growth in high-value solutions, and further leverage its position in the biologics and GLP1 markets.
At the time of this announcement, STVN was trading at $17.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $13.91 to $28.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.